Prognostic Impact of Postoperative Skeletal Muscle Decrease in Non-Small Cell Lung Cancer.

Prognostic Impact of Postoperative Skeletal Muscle Decrease in Non-Small Cell Lung Cancer. Ann Thorac Surg. 2019 Oct 23;: Authors: Takamori S, Tagawa T, Toyokawa G, Shimokawa M, Kinoshita F, Kozuma Y, Matsubara T, Haratake N, Akamine T, Hirai F, Honda H, Maehara Y Abstract BACKGROUND: Preoperative skeletal muscle loss was reported to be associated with a postoperative poor prognosis in non-small cell lung cancer (NSCLC) patients. The aim of this study was to elucidate the relationship between the change in skeletal muscle mass following surgery and the postoperative outcomes in NSCLC patients. METHODS: The data analyzed 204 NSCLC patients who had undergone curative lung resection and whose preoperative and postoperative (1 year) computed tomography images were available. The skeletal muscle area (SMA) at the 12th thoracic vertebra level was used. Post/pre ratio was defined as postoperative normalized SMA (cm2/m2) divided by preoperative normalized SMA. The cut-off value was set to post/pre ratio = 0.9. Neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, modified Glasgow prognostic score, and prognostic nutritional index were used to estimate change in the nutritional status. RESULTS: Seventy patients (34.3%) were classified into the SMA-decreased group. Low body mass index was significantly associated with the SMA-decreased patients (p = 0.019). The SMA-decreased status was found to be an independent prognostic factor for overall survival a...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Surg Source Type: research

Related Links:

Publication date: Available online 20 February 2020Source: The Annals of Thoracic SurgeryAuthor(s): Tingting Wang, Jiajun Deng, Yunlang She, Lei Zhang, Bin Wang, Yijiu Ren, Junqi Wu, Dong Xie, Xiwen Sun, Chang ChenAbstractBackgroundWe aimed to explore the predictive value of radiomics signature for the recurrence-free survival (RFS) in patients with resected stage I non-small-cell lung cancer (NSCLC).MethodsFrom January 2009 to December 2011, patients with resected stage I NSCLC were divided into sub-solid and pure-solid groups according to presence of ground glass opacity (GGO) in computed tomography (CT). A total of 107 ...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Abstract BACKGROUND: We aimed to explore the predictive value of radiomics signature for the recurrence-free survival (RFS) in patients with resected stage I non-small-cell lung cancer (NSCLC). METHODS: From January 2009 to December 2011, patients with resected stage I NSCLC were divided into sub-solid and pure-solid groups according to presence of ground glass opacity (GGO) in computed tomography (CT). A total of 107 extracted radiomics features were reduced to 8 features by using LASSO-Cox analysis to develop a radiomics signature for RFS prediction. Univariate and multivariate survival analyses were applie...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Surg Source Type: research
Objectives: To identify a computed tomography (CT)-based radiomic signature for predicting progression-free survival (PFS) in stage IV anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) patients treated with tyrosine kinase inhibitor (TKI) crizotinib.Materials and Methods: This retrospective proof-of-concept study included a cohort of 63 stage IV ALK-positive NSCLC patients who had received TKI crizotinib therapy for model construction and validation. Another independent cohort including 105 stage IV EGFR-positive NSCLC patients was also used for external validation in EGFR-TKI treatment. We initi...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Preoperative SUVmax of primary lesions is a predictor of pathological nodal metastases in peripheral cN0 NSCLC with tumor size  ≤2 cm. Primary tumor SUVmax is associated with key clinicopathological features and prognosis of patients with peripheral cN0 NSCLC with tumor size ≤2 cm. AbstractObjectiveIn this cohort study, we determined the clinical value of the maximum standardized uptake value (SUVmax) of primary tumors in non ‐small cell lung cancer (NSCLC).Study DesignA retrospective review of NSCLC patients was performed from January 2011 to December 2017. Peripheral cN0 NSCLC patients with tu...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Centrally located primary lung tumour defined as visibility of the tumor on video bronchoscopy in the main stem, lobair or segment bronchi or tumor adherent to or in between segment bronchi or blood vessels on computed tomography. (DLCA-S definition)
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
This study aimed to assess dose distributions for stage I non-small cell lung cancer (NSCLC) with passive scattering carbon-ion radiotherapy (C-ion RT) using daily computed tomography (CT) images. MATERIALS AND METHODS: We enrolled 10 patients with stage I NSCLC and acquired a total of 40 pre-fractional CT image series under the same settings as the planning CT images. These CT images were registered with planning CT images for dose evaluation using both bone matching (BM) and tumor matching (TM). Using deformable image registration, we generated accumulated doses. Moreover, the volumetric dose parameters were compare...
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Tags: Radiother Oncol Source Type: research
ConclusionsL3 muscle indexLow is an independent predictor of worse outcomes in NSCLC patients treated with anti-PD-1 inhibitors.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: L3 muscle index Low is an independent predictor of worse outcomes in NSCLC patients treated with anti-PD-1 inhibitors. PMID: 32025867 [PubMed - as supplied by publisher]
Source: Clin Med Res - Category: Research Authors: Tags: J Cancer Res Clin Oncol Source Type: research
In conclusion, SM loss may be a predictive factor of poor outcomes in NSCLS patients undergoing nivolumab therapy.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
ConclusionsTumor volume growth rate after nadir in ALK-rearranged NSCLC patients treated with crizotinib was obtained, providing objective reference values that can inform physicians when deciding to keep their patients on ALK directed therapy with slowly progressing lung cancer.
Source: European Journal of Radiology Open - Category: Radiology Source Type: research
More News: Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | CT Scan | Lung Cancer | Non-Small Cell Lung Cancer | Nutrition | Study